Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation
Keyword(s):
Egfr Tki
◽
2014 ◽
Vol 32
(8)
◽
pp. 859-863
◽
2011 ◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7537-7537
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):